Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: INHALON BIOPHARMA, INC.
Awarding agency: Department of Defense / Defense Health Agency
Funding agency: Department of Defense / Defense Health Agency
Period of performance: 2024-09-23 to 2026-12-22
Current total value of award: $2234650
Description: DEVELOPING IN-007 AS A WIDELY DEPLOYABLE INHALED TREATMENT AGAINST PATHOGENS UTILIZING HUMAN ACE2 FOR VIRAL ATTACHMENT AND ENTRY